A study highlights the use of burosumab as a bridging therapy for patients with autosomal dominant hypophosphatemic rickets experiencing femoral fracture nonunion and iron deficiency. This research contributes to understanding treatment options for this rare condition.
burosumab as bridging therapy in autosomal dominant hypophosphatemic rickets with femoral fracture nonunion and iron deficiency
Original title: “Burosumab as bridging therapy in autosomal dominant hypophosphatemic rickets with femoral fracture nonunion and iron deficiency.”